Hologic, Inc. (NASDAQ:HOLX) – Analysts at Gabelli boosted their FY2018 earnings estimates for shares of Hologic in a report issued on Tuesday. Gabelli analyst S. Wojda now expects that the medical equipment provider will earn $2.30 per share for the year, up from their previous estimate of $2.15. Gabelli also issued estimates for Hologic’s FY2019 earnings at $2.60 EPS, FY2020 earnings at $2.85 EPS and FY2021 earnings at $3.00 EPS.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 EPS.
Shares of Hologic (HOLX) traded up $0.16 during midday trading on Thursday, reaching $43.71. The company’s stock had a trading volume of 3,060,034 shares, compared to its average volume of 1,908,935. The firm has a market cap of $12,006.02, a PE ratio of 16.56, a PEG ratio of 2.08 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a 52-week low of $35.76 and a 52-week high of $46.80.
In other news, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Insiders have sold a total of 12,099 shares of company stock valued at $487,223 in the last three months. 0.79% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the company. Koch Industries Inc. increased its holdings in Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 1,142,138 shares in the last quarter. Picton Mahoney Asset Management increased its holdings in Hologic by 8.1% in the 2nd quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after purchasing an additional 4,300 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its holdings in Hologic by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock worth $8,975,000 after purchasing an additional 3,391 shares in the last quarter. Royce & Associates LP acquired a new position in Hologic in the 2nd quarter worth about $908,000. Finally, Cipher Capital LP increased its holdings in Hologic by 57.9% in the 3rd quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after purchasing an additional 43,146 shares in the last quarter. 97.67% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/13/fy2018-eps-estimates-for-hologic-inc-holx-lifted-by-analyst.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
What are top analysts saying about Hologic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic and related companies.